Drug Profile
Research programme: AOC3 protein inhibitors - Faron/Priaxon
Alternative Names: Farbetic; FP-1101; FP-1102; Vitamin B1 analoguesLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Faron Pharmaceuticals; Priaxon
- Class Small molecules; Vinca alkaloids
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Vascular-disorders in Finland (PO)
- 02 Mar 2020 Preclinical development for AOC3 inhibitors is ongoing in Finland (PO)
- 02 Mar 2020 Faron Pharmaceuticals acquires rights for the AOC3 inhibitors technology from University of Turku